Mirvaso Gel (Brimonidine 0.33%)

Mirvaso is the new FDA approved treatment from Galderma that was previously known as Sansrosa, CD07805/47 and Col-118. Mirvaso is the only topical treatment officially approved for the relief of the red face of rosacea. Mirvaso is Brimonidine Topical Gel 0.33% and is available in 30g and 45g tubes, on prescription only. It is used once per day and can last as long as 12 hours.

See below for Mirvaso User Reviews, news and updates

Recent Rosacea Blog Posts

Galderma defending against Actavis Generic Mirvaso

Following on from the large trial announcement by Actavis last year, Galderma has started a suit against Actavis to prevent the sale of Generic Mirvaso. Actavis has filed an abbreviated new drug application with the FDA. Galderma is seeking to use a series of patents to block Actavis from marketing their Brimonidine Topical Gel, 0.33%. […]

Continue Reading

Severe Mirvaso Rebound Redness: Dermatitis Medicamentosa

(Click image for a larger view). (Left) One hour following application of Mirvaso with initial blanching and improvement of baseline erythema. (Right) Twelve hours following application of Mirvaso with significant increase in baseline erythema. A recently published short article in Dermatology Online Journal is proposing the use of the term Dermatitis Medicamentosa to describe one […]

Continue Reading

Mirvaso in the real world: 10-20% have rebound redness

This just published paper in the Journal of Drugs in Dermatology has an interesting statement that is an admission that Mirvaso in the real world is not performing as well as seen in the Phase III Clinical Trials. This fact will come as no surprise to those following the online reviews for Mirvaso – there […]

Continue Reading

Actavis to trial Mirvaso competitor

An interesting development in rosacea clinical trials is the emergence of a new company called Actavis. Actavis have listed a large trial where they plan to test their Brimonidine Gel against Galderma’s recently FDA approved Brimonidine-based Mirvaso Gel. The large Phase 3 trial will compare the response after 7 days. Up to 462 patients in […]

Continue Reading

Galderma offers physicians advice for Mirvaso Rebound Redness

Galderma have added a page to the Mirvaso web site to guide doctors dealing with the potential for “rebound” by users of Mirvaso. This would seem to confirm that Galderma is aware that there are users of MIRVASO who are experiencing adverse events. The use of double quotes around “rebound” and “worsening” is interesting and […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.